Mangafodipir trisodium (Mn-DPDP) is one of several recently developed targeted hepatobiliary agents. Contrast-to-noise measurements have shown favorable results for Mn-DPDP-enhanced MR as compared with nonenhanced T1- and T2-weighted images. An improved capability for lesion detection and the ability to characterize tumors of hepatocellular origin have been demonstrated. The prolonged enhancement obtained with Mn-DPDP provides an extended window of time during which effective contrast is maintained as compared with traditional extracellular contrast agents. This report details the experimental and initial clinical experience with Mn-DPDP-enhanced MR imaging of the abdomen.
|Original language||English (US)|
|Number of pages||13|
|Journal||Magnetic resonance imaging clinics of North America|
|State||Published - Mar 21 1996|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging